# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β mono...
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades t...
Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (NASDAQ:AVTX) from Perform to Outperform and announces $35 p...